RxDoctor Payments DataLook up a doctor →

Nithi Anand, MD

Neurology · Marietta, GANPI 1346287760

Payments from drug & device makers

$73,936in general payments, 2019–2025

Across 651 payments — averaging $113.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$37K
  • Amgen$25K
  • Lilly USA, LLC$2K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Lundbeck LLC$2K
  • UCB, Inc.$441
  • plus $6K from 49 others

What the payments were for

  • Consulting fees$1,3602%
  • Speaking & faculty fees$59,25180%
  • Grants$420%
  • Travel & lodging$1,1382%
  • Food & beverage$12,12216%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,936 in reported general payments places this provider in the 85th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$250,275
Medicare patients
544
Services billed
24,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4619$262,335
IngrezzaValbenazine Tosylate12$101,323
UbrelvyUbrogepant54$89,432
QuliptaAtogepant47$61,908
Nurtec OdtRimegepant Sulfate29$44,206
Aimovig AutoinjectorErenumab-Aooe42$35,250
Emgality PenGalcanezumab-Gnlm39$26,834
KeppraLevetiracetam12$13,512
Buprenorphine22$8,479
Lacosamide32$7,160
AdderallDextroamphetamine/Amphetamine11$7,093
Dimethyl Fumarate19$5,559
Carbidopa-LevodopaCarbidopa/Levodopa177$5,198
Memantine Hcl259$4,889
Levetiracetam118$4,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$96$262,33519 claims
AbbVieUbrelvy, Qulipta$36,893$151,340101 claims
Neurocrine Biosciences, Inc.Ingrezza$101$101,32312 claims
PfizerNurtec Odt$384$44,20629 claims
Upsher-smith Laboratories LLCTopiramate$141$1,015111 claims
Lilly USA, LLCOlanzapine$2,479$66217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 506 neurology providers in Georgia.

Other neurology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →